Tag

natalizumab

  • Forum

    Updated recommendations to minimise the risk of the rare brain infection PML with Tysabri – Comment to EMA recommendation

    March 1, 2016
    After more than a decade from the natalizumab approval, most MS specialists consider this biological therapy as one of the most efficient drugs that we have nowadays to treat relapsing-remitting MS patients. However, the problem we have to face when we start to use natalizumab is the risk of the occurrence of progressive multifocal leukoencephalopathy (PML) in some patients.
  • Forum

    Forum: Attempts to cope with the Science Avalanche

    July 1, 2014
    he first paper that I would like to point out to our readers is “Use of a novel high-resolution magnetic resonance neurography protocol to detect abnormal dorsal root ganglia in Sjögren patients with neuropathic pain: case series of 10 patients and review of the Literature”, published in Medicine; May 2014; Vol. 93; Issue 3 ; p. 121-134.